Episode 14 - Two Years of Medevise: A Conversation with the Medevise Board

On this episode of the BOEI Podcast, the Medevise board of directors takes a look back over the last two years since the company was founded to reflect on the original mission, the market need that Medevise fills, its rapid growth, and the vision for what’s next. 

Speakers:

• Kristine Morrill, Founder and President of Medevise Consulting

• Paul Bikard, Chief Financial Officer

• Bernie Haffey, Board Member

• Michael Mrochen, Board Member

• Vance Thompson, Board Member

• Tom Ruggia, Board Member

Board member not present: Gerd Auffarth

Key Takeaways:

The Medevise board discussed the original promise of Medevise when it was founded in 2021, and what factors led the board members to commit to the company:

• Medevise addresses the biggest challenges that the board members have seen companies falter on and eventually fail

• Unmet market need: There are other businesses that provide each one of our primary services individually (market access and reimbursement, clinical and the regulatory, and communications), but there's no other group in the world doing all of them together

• High-level expertise in each discipline providing and business perspective, clinical perspective, regulatory perspective, clinician perspective

• Companies can access that expertise very quickly to address their specific need

• Medevise has the experience and processes to manage the complexity of the European market, including differing regulatory environments, and cultural and communications nuances.

• Committed to a high performance management system for strategic and intentional growth and operations

• Full-time dedicated staff

• Central point of contact for consolidated European market strategy and execution, rather than a complex network of multiple partners / distributors / regulatory opinions

The board also considered what they envision in Medevise’s future:

• Continued growth on the current foundation, and as global expansions become more complex, continuing to serve as a European partner for faster and smoother go-to-market

• Serving medical device markets outside the reimbursed system

Learn more about the Medevise board on our website. For more engaging topics on medical device innovation, please follow Medevise on LinkedIn.